Mongelli Michele, Lorusso Domenica, Zanagnolo Vanna, Pignata Sandro, Colombo Nicoletta, Cormio Gennaro
Obstetrics and Gynecology Unit, University of Bari "Aldo Moro", 70124 Bari, Italy.
Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, 00168 Rome, Italy.
Diagnostics (Basel). 2024 May 31;14(11):1159. doi: 10.3390/diagnostics14111159.
Cancer-associated thrombosis is the second leading cause of death in cancer patients, and its incidence has been increasing in recent years. This survey was aimed at gathering information regarding the management of thromboembolic prophylaxis within the MITO (Multicenter Italian Trials in Ovarian Cancer)-MaNGO (Mario Negri Gynecologic Oncology) groups. We designed a self-administered, multiple-choice online questionnaire available only for MITO-MaNGO members for one month, starting in May 2022 and ending in June 2022. We processed one response form per center, and 50 responses were analyzed, with most of the respondents (78%) over 40 years old. We found that 82% of them consider thromboembolic prophylaxis in gynecologic oncology to be relevant. In 82% of the centers, a standardized protocol on venous thromboembolism (VTE) prophylaxis is used, which is applied to both patients undergoing surgery and those undergoing chemotherapy. In the remaining 18% of centers, prophylaxis is used exclusively for patients undergoing chemotherapy treatment. Prophylaxis of patients undergoing surgery and chemotherapy treatment is managed in most cases by the surgeon (72%) and oncologist (76%), respectively. Only 26% of respondents use a thromboembolic risk assessment scale, and of these, those used are the Caprini Score (6%), Khorana Score (6%), and Wells Score (2%). The respondents have good knowledge of low-molecular-weight heparin (90%) and average knowledge of dicumarolics (40%), direct oral anticoagulants (DOACs) (68%), and antiplatelet agents (40%). The results of our survey indicate that there is a good awareness of thromboembolic prophylaxis in gynecologic oncology. Nevertheless, it is used less in outpatients than in patients undergoing surgery. Moreover, the thromboembolic risk assessment scores are barely used.
癌症相关血栓形成是癌症患者的第二大死因，且近年来其发病率一直在上升。这项调查旨在收集有关意大利多中心卵巢癌试验（MITO）-马里奥·内格里妇科肿瘤学组（MaNGO）内血栓栓塞预防管理的信息。我们设计了一份自填式多项选择题在线问卷，从2022年5月开始至2022年6月结束，仅面向MITO-MaNGO成员开放一个月。我们每个中心处理一份回复表，共分析了50份回复，大多数受访者（78%）年龄超过40岁。我们发现，其中82%的人认为妇科肿瘤学中的血栓栓塞预防很重要。在82%的中心，使用了关于静脉血栓栓塞（VTE）预防的标准化方案，该方案适用于接受手术的患者和接受化疗的患者。在其余18%的中心，预防措施仅用于接受化疗的患者。接受手术和化疗的患者的预防措施在大多数情况下分别由外科医生（72%）和肿瘤学家（76%）管理。只有26%的受访者使用血栓栓塞风险评估量表，其中使用的是卡普里尼评分（6%）、霍拉纳评分（6%）和韦尔斯评分（2%）。受访者对低分子量肝素的了解较好（90%），对双香豆素类药物（40%）、直接口服抗凝剂（DOACs）（68%）和抗血小板药物（40%）的了解一般。我们的调查结果表明，妇科肿瘤学中对血栓栓塞预防有较好的认识。然而，门诊患者的使用少于接受手术的患者。此外，血栓栓塞风险评估评分几乎未被使用。
